

References

1-183

1. Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. *Lancet*. 2017;390:849-860.
2. Hayes, Inc. Hayes Emerging Technology Report. Luxturna (Voretigene neparvovec-rzyl). Lansdale, PA: Hayes, Inc.; 09/21/2020. Accessed 01/11/2022.
3. Naso MF, Tomkowicz B, Perry WL, et al. Adeno-associated virus (AAV) as a vector for gene therapy. 2017;31(4):317-334.
4. Kumaran N, Moore AT, Weleber RG, et al. Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions. *Br J Ophthalmol*. 2017;101(9):1147-1154.
5. Campa C, Gallenga CE, Bolletta E, et al. The role of gene therapy in the treatment of retinal diseases: a review. *Curr Gene Ther*. 2017;17(3):194-213.
6. Chung DC, McCague S, Yu ZF, et al. Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. *Clin Exp Ophthalmol*. 2017;46(3):247-259.
7. Ashtari M, Nikonova ES, Marshall KA, et al. The role of the human visual cortex in assessment of the long-term durability of retinal gene therapy in follow-on RPE65 clinical trial patients. 2017;124(6):873- 883.